ZELTIQ® Aesthetics Launches New CoolFit Applicator Globally

ZELTIQ Aesthetics, Inc. (Nasdaq: ZLTQ), a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology, today announced the global introduction of CoolFit, the newest addition to the applicator platform for the CoolSculpting System, at the American Academy for Dermatology (AAD) annual meeting in Miami.

“We are committed to optimizing patient outcomes and are focused on providing additional applicators that are both more efficient and that treat a broader range of patients,” said Mark Foley, President and Chief Executive Officer of ZELTIQ. “CoolFit’s configuration and larger treatment area provides physicians with even more options when assessing patients and developing truly customized treatment plans to achieve the desired results.”

CoolFit’s advanced engineering design features a flat applicator cup and 38 percent larger cooling plates than the CoolCore applicator. This enables treatment of different areas on more body types than ever before. With CoolFit, it is possible for more patients to take advantage of CoolSculpting’s unique cooling approach that selectively targets and destroys fat, something heat-based procedures cannot replicate.

“The CoolFit design allows me to treat harder to reach areas and, for the first time, longer fat bulges, which is attracting new patients to my practice,” said Brian Zelickson, MD, Medical Director of Zel Skin & Laser Specialists in Edina, Minn. “My CoolSculpting patients who are being treated with CoolFit are very satisfied with their individual results.”

The fifth applicator to be introduced for use with CoolSculpting, the CoolFit applicator allows physicians to easily customize patients’ treatment plans, particularly in areas with longer and hard-to-reach fat bulges.

“CoolFit really rounds out the CoolSculpting applicator platform and has been a welcome addition to my practice because of its versatility,” said Jay Burns, MD, Medical Director of EpiCentre Park Lane in Dallas and EpiCentre Legacy in Plano, Texas. “In combination, all the applicators broaden the scope of treatable patients and their respective outcomes.”

In the United States and Taiwan, CoolSculpting is cleared for non-invasive fat reduction in the abdomen and flank. In other international markets, CoolSculpting is cleared for general non-invasive fat reduction. More than 500,000 CoolSculpting treatments have been performed worldwide. CoolSculpting results in an undeniable reduction of fat in the treated areas, and patients can start to see results as soon as three weeks following treatment, with the most dramatic results occurring over a period of two to four months in most patients. Every patient case is unique which is why ZELTIQ recommends a customized treatment plan as part of the initial consultation. After the initial treatment is complete, patients can attain further reductions with additional treatments, resulting in even more fat loss.

About CoolSculpting®

CoolSculpting is a non-surgical, clinically proven procedure designed to selectively reduce fat bulges in problem areas using a patented cooling technology. Cleared by the FDA for noninvasive fat reduction in the abdomen and flank, it is a procedure that gently cools unwanted fat cells in the body to induce a natural, controlled elimination of fat cells. It is designed to reduce fat bulges in treated areas of the body without harming surrounding tissue. CoolSculpting is available through an elite network of CoolSculpting Centers worldwide. Dermatologists, plastic surgeons and leading aesthetic specialists that offer CoolSculpting can be found at www.coolsculpting.com.

Be sure to follow CoolSculpting on Facebook, Twitter and YouTube.

About ZELTIQ® Aesthetics, Inc.

ZELTIQ is a medical technology company focused on developing and commercializing products utilizing its proprietary controlled-cooling technology platform. ZELTIQ’s first commercial product, the CoolSculpting System, is designed to selectively reduce stubborn fat bulges that may not respond to diet or exercise. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. CoolSculpting utilizes patented technology of precisely controlled cooling to reduce the temperature of fat cells in the treated area, which is intended to cause fat cell elimination through a natural biological process known as apoptosis, without causing scar tissue or damage to the skin, nerves, or surrounding tissues. ZELTIQ developed CoolSculpting to safely, noticeably, and measurably reduce the fat layer within a treated fat bulge without requiring the patient to diet or exercise.

Zeltiq Aesthetics, Inc. (NASDAQ:ZLTQ)
Historical Stock Chart
From Jun 2024 to Jul 2024